Focus: Sequoia Vaccines is a biotechnology company focused on antibacterial small molecules and vaccines for urinary tract infections (UTIs), addressing unmet needs in infectious disease. Founded in 2012 and headquartered in St. Louis, the company operates as a public-stage biotech with a specialized therapeutic focus.
Profile data last refreshed 3h ago · AI intelligence enriched 1w ago
Hot — 30 jobs added in 30d
Net +28 (30 new, 2 removed). Aggressive expansion phase.
A specialized infectious disease biotech with public status and commercial operations, but severely limited transparency on pipeline depth, clinical progress, and scientific productivity makes this a high-uncertainty career choice.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Sequoia Vaccines
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Sequoia Vaccines's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles